CORTISPORIN Drug Patent Profile

Which patents cover Cortisporin, and what generic alternatives are available?

Cortisporin is a drug marketed by Monarch Pharms and Casper Pharma Llc and is included in five NDAs.

The generic ingredient in CORTISPORIN is hydrocortisone; neomycin sulfate; polymyxin b sulfate. There are sixty-seven drug master file entries for this compound. Fourteen suppliers are listed for this compound. Additional details are available on the hydrocortisone; neomycin sulfate; polymyxin b sulfate profile page.

Summary for CORTISPORIN

US Patents:	0
Applicants:	2
NDAs:	5

US Patents and Regulatory Information for CORTISPORIN

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Monarch Pharms	CORTISPORIN	hydrocortisone acetate; neomycin sulfate; polymyxin b sulfate	CREAM;TOPICAL	050218-001	Aug 9, 1985		DISCN	Yes	No
Monarch Pharms	CORTISPORIN	hydrocortisone; neomycin sulfate; polymyxin b sulfate	SOLUTION/DROPS;OTIC	050479-001	Approved Prior to Jan 1, 1982		DISCN	Yes	No
Casper Pharma Llc	CORTISPORIN	bacitracin zinc; hydrocortisone; neomycin sulfate; polymyxin b sulfate	OINTMENT;OPHTHALMIC	050416-002	Approved Prior to Jan 1, 1982		DISCN	Yes	No

CORTISPORIN: PATENT LANDSCAPE AND INVESTMENT FUNDAMENTALS ANALYSIS

Last updated: February 19, 2026

Cortisporin, a combination antibiotic and corticosteroid ophthalmic suspension, faces a mature market with multiple generic competitors. Its patent expiration in the late 1990s has led to significant price erosion and limited opportunities for novel patent-driven growth. Investment consideration hinges on market share defense, potential lifecycle management strategies, and competition from newer therapeutic agents.

WHAT IS THE CORE PATIENT POPULATION FOR CORTISPORIN?

The primary patient population for Cortisporin (hydrocortisone/neomycin/polymyxin B ophthalmic suspension) includes individuals suffering from corticosteroid-responsive inflammatory ocular conditions complicated by bacterial infection. This encompasses a range of conditions such as:

• Anterior Segment Inflammation: This includes conditions like conjunctivitis, keratitis, uveitis, and iritis where inflammation of the front part of the eye is present.
• Bacterial Ocular Infections: The antibiotic components target common bacterial pathogens responsible for ocular infections, including Staphylococcus aureus, Escherichia coli, Haemophilus influenzae, Klebsiella pneumoniae, Neisseria species, Pseudomonas aeruginosa, and Streptococcus species.
• Post-Surgical Ocular Inflammation and Infection: Cortisporin is frequently prescribed following ophthalmic surgery to manage inflammation and prevent post-operative infection.

The prevalence of these conditions directly influences market demand. For example, allergic conjunctivitis, a common inflammatory condition, affects a significant portion of the population, driving demand for anti-inflammatory eye drops. Similarly, the incidence of bacterial eye infections, though generally lower than allergic conjunctivitis, requires effective antimicrobial treatment.

WHAT IS THE PATENT HISTORY AND CURRENT PATENT STATUS OF CORTISPORIN?

Cortisporin's intellectual property landscape is characterized by the expiration of its foundational patents. The original patents covering the combination formulation of hydrocortisone, neomycin, and polymyxin B have long since expired.

• Original Composition of Matter Patents: These patents, which would have protected the initial discovery of the drug combination, expired in the late 1990s. Specific expiration dates are not publicly detailed for expired patents but generally fall within the typical 20-year patent term from filing.
• Exclusivity Periods: Following patent expiration, the drug entered the generic market. Hatch-Waxman Act provisions allow for periods of market exclusivity for New Chemical Entities (NCEs) and specific formulations, but Cortisporin, as an older combination product, did not benefit from extended exclusivity beyond its initial patent protection.
• Current Patent Landscape: There are no active patents that would prevent generic manufacturers from producing and marketing the standard Cortisporin formulation. While new formulations, delivery systems, or novel uses could theoretically be patented, the core product is off-patent. This has led to a highly competitive generic market.

The absence of active patent protection for the original formulation means that the competitive advantage for any single manufacturer is primarily based on manufacturing efficiency, distribution networks, and brand recognition rather than exclusivity rights.

WHO ARE THE KEY COMPETITORS AND WHAT IS THE MARKET COMPETITION DYNAMIC?

The market for Cortisporin is highly competitive, dominated by generic manufacturers offering lower-cost alternatives.

• Generic Manufacturers: Numerous pharmaceutical companies produce generic versions of hydrocortisone/neomycin/polymyxin B ophthalmic suspension. These include, but are not limited to, companies such as:

  • Teva Pharmaceuticals
  • Sandoz (a division of Novartis)
  • Apotex
  • Bausch Health
  • Akorn Pharmaceuticals
  • Various smaller generic producers.

• Competition Dynamics:

  • Price Erosion: The presence of multiple generic suppliers has led to significant price erosion. The cost of generic Cortisporin is substantially lower than the branded product would have been during its patent-protected period.
  • Market Share: While branded Cortisporin may retain some market share due to physician familiarity and patient preference, the vast majority of prescriptions are filled with generic equivalents due to cost savings.
  • Therapeutic Alternatives: Competition also comes from newer, single-agent or combination ophthalmic medications that may offer improved efficacy, broader spectrum coverage, or better tolerability profiles. Examples include:
    • Fluoroquinolone-based antibiotic eye drops (e.g., moxifloxacin, levofloxacin) often used as first-line agents for certain bacterial keratitis.
    • Steroid-only ophthalmic suspensions (e.g., loteprednol, fluorometholone) for inflammatory conditions without infection.
    • Combination drops with more advanced antibiotic or steroid components.

The market is characterized by a high volume of sales with low profit margins per unit, driven by cost-conscious healthcare systems and payers.

WHAT IS THE CURRENT MARKET SIZE AND GROWTH PROJECTION FOR CORTISPORIN AND ITS GENERIC EQUIVALENTS?

Estimating the precise market size and growth projection for Cortisporin specifically, separate from all other ophthalmic antibiotic-steroid combinations, is challenging due to the prevalence of generic substitution and broad categorization in market research reports. However, the market for ophthalmic antibiotic-corticosteroid combinations as a class is substantial and generally stable, influenced by the prevalence of the target conditions.

• Market Size (Class Estimation): The global ophthalmic anti-infective drugs market, which includes antibiotic-corticosteroid combinations, was valued at approximately USD 2.5 billion in 2022 and is projected to grow at a compound annual growth rate (CAGR) of around 4-5% through 2028. (Source: Various market research reports, e.g., Mordor Intelligence, Grand View Research). Cortisporin and its direct generic equivalents represent a significant portion of this market, particularly in the lower-cost segments.
• Growth Drivers:
  • Increasing Ocular Infections: The incidence of bacterial eye infections, though treatable, remains a consistent driver.
  • Rising Prevalence of Inflammatory Eye Conditions: Allergic conjunctivitis and other inflammatory conditions that require steroid treatment are widespread.
  • Aging Population: An aging demographic may lead to an increased incidence of age-related eye conditions requiring treatment.
  • Growth in Emerging Markets: Increased access to healthcare and diagnostic capabilities in developing economies contribute to market expansion.
• Growth Restraints:
  • Generic Competition: As discussed, intense price competition among generic manufacturers limits revenue growth.
  • Development of Newer Therapies: Advancements in ophthalmology have introduced new classes of antibiotics and anti-inflammatories with potentially better efficacy or safety profiles, which can displace older treatments.
  • Stricter Regulatory Scrutiny: Requirements for drug safety and efficacy can influence product lifecycles.

For Cortisporin specifically, the growth projection is likely to mirror the overall market for its therapeutic class but with a muted revenue trajectory due to its mature, genericized status. Volume growth may be positive, but revenue growth will be constrained by pricing pressure.

WHAT ARE THE KEY MANUFACTURING AND SUPPLY CHAIN CONSIDERATIONS FOR CORTISPORIN?

The manufacturing and supply chain for Cortisporin involve several critical aspects, particularly given its generic status and the need for cost-efficiency.

• Active Pharmaceutical Ingredient (API) Sourcing:
  • Neomycin Sulfate: Typically sourced from fermentation processes.
  • Polymyxin B Sulfate: Also derived from bacterial fermentation (Bacillus polymyxa).
  • Hydrocortisone: A synthetic corticosteroid.
  • Global Sourcing: APIs are often sourced from manufacturers in Asia (e.g., China, India) and Europe, where production costs can be lower. Ensuring quality, consistency, and regulatory compliance of API suppliers is paramount.
• Formulation and Drug Product Manufacturing:
  • Sterile Manufacturing: Ophthalmic suspensions require sterile manufacturing environments to prevent microbial contamination. This involves specialized facilities, rigorous quality control (QC), and adherence to Good Manufacturing Practices (GMP).
  • Equipment: Specialized filling and packaging equipment for sterile liquids is required.
  • Excipients: The formulation includes preservatives (e.g., benzalkonium chloride), viscosity enhancers, and pH adjusters. Sourcing of these excipients must also meet pharmaceutical standards.
• Packaging and Distribution:
  • Ophthalmic Dropper Bottles: Typically polyethylene dropper bottles designed for precise, sterile delivery.
  • Cold Chain Requirements: While Cortisporin is generally a room-temperature stable product, specific storage conditions must be maintained throughout the supply chain to ensure product integrity.
  • Global Distribution Networks: Manufacturers and distributors must have established networks to reach pharmacies and healthcare providers globally.
• Regulatory Compliance:
  • FDA, EMA, and Other Authorities: Manufacturing facilities and processes must comply with regulations set by health authorities in target markets (e.g., FDA in the U.S., EMA in Europe). This includes regular inspections and adherence to GMP guidelines.
  • ANDA Filings: Generic manufacturers must file Abbreviated New Drug Applications (ANDAs) with regulatory bodies, demonstrating bioequivalence to the reference listed drug.

The competitive landscape necessitates efficient manufacturing processes to minimize costs while maintaining high quality and regulatory standards. Supply chain disruptions, such as API shortages or manufacturing issues, can significantly impact availability and profitability.

WHAT ARE POTENTIAL RISKS AND OPPORTUNITIES FOR CORTISPORIN INVESTMENTS?

Investing in companies that manufacture or distribute Cortisporin or similar ophthalmic antibiotic-steroid combinations presents a specific set of risks and opportunities.

Risks:

• Intense Generic Competition and Price Erosion: The most significant risk is the ongoing price pressure from numerous generic competitors, limiting profit margins and revenue growth.
• Emergence of Superior Therapies: New antibiotic classes, novel anti-inflammatory agents, or combination products with improved efficacy, safety, or convenience profiles can erode market share. For instance, fluoroquinolones have become first-line treatments for many bacterial keratitis cases.
• Regulatory Scrutiny and Quality Issues: Manufacturing of sterile ophthalmic products is subject to strict regulatory oversight. Any quality control failures, recalls, or warning letters from regulatory agencies can lead to significant financial and reputational damage.
• Supply Chain Vulnerabilities: Dependence on specific API suppliers or manufacturing sites can create vulnerabilities to shortages, geopolitical instability, or natural disasters.
• Shifting Prescribing Patterns: Changes in clinical guidelines or physician preferences can lead to a decline in the use of older, established drugs like Cortisporin.
• Limited Innovation Potential: As a mature, off-patent product, there are few opportunities for significant R&D-driven growth through novel formulations or applications for the core Cortisporin combination.

Opportunities:

• Stable Demand from Large Patient Populations: The underlying conditions treated by Cortisporin (bacterial eye infections and inflammation) remain prevalent, ensuring a consistent baseline demand for effective, affordable treatments.
• Cost-Effectiveness for Healthcare Systems: In cost-sensitive healthcare environments, generic Cortisporin offers a cost-effective treatment option, which can sustain its market presence.
• Emerging Market Penetration: As healthcare access improves in emerging economies, there is potential for increased volume sales of affordable generic ophthalmic medications.
• Lifecycle Management (Limited Scope): While core patent protection is gone, potential for minor improvements (e.g., preservative-free formulations, enhanced packaging for better delivery) could offer niche market differentiation, though this is less impactful than novel patent-backed innovation.
• Portfolio Diversification: For pharmaceutical companies, Cortisporin can be part of a broader portfolio of ophthalmic products, contributing to overall revenue and market presence. Its stable, albeit low-margin, revenue stream can help support investment in newer, higher-growth areas.

Investment viability depends on a company's ability to manage manufacturing costs efficiently, maintain high-quality standards, navigate the competitive generic market, and leverage distribution strengths.

KEY TAKEAWAYS

Cortisporin, a combination ophthalmic antibiotic-corticosteroid, operates in a mature, highly competitive generic market. Its foundational patents expired in the late 1990s, resulting in significant price erosion and the entry of numerous manufacturers. The drug treats inflammatory ocular conditions complicated by bacterial infections, serving a broad patient population. While the overall ophthalmic anti-infective market is projected to grow, Cortisporin's individual revenue growth will be constrained by intense price competition and the emergence of newer therapeutic agents. Manufacturing requires adherence to strict sterile GMP standards, with API sourcing often global. Key investment risks include price erosion, superior competitor products, and regulatory issues. Opportunities lie in stable demand, cost-effectiveness, and emerging market penetration, but innovation potential for the core product is minimal.

FAQS

1. What is the primary reason for Cortisporin's lack of patent protection? Cortisporin's original formulation patents expired in the late 1990s, making it eligible for generic manufacturing under established pharmaceutical regulations.

2. How does the generic competition affect Cortisporin's profitability? Intense generic competition leads to significant price erosion, drastically reducing profit margins per unit and limiting overall revenue growth potential for manufacturers of the drug.

3. Are there any newer formulations of Cortisporin that offer patent protection? While minor formulation improvements or delivery systems could theoretically be patented, the core combination of hydrocortisone, neomycin, and polymyxin B in its standard ophthalmic suspension form is off-patent, and no significant new patent-protected variations have emerged to dominate the market.

4. What therapeutic classes of drugs are considered direct competitors to Cortisporin? Direct competitors include other ophthalmic antibiotic-corticosteroid combinations and single-agent treatments such as fluoroquinolone antibiotic eye drops for infections and steroid-only eye drops for inflammation.

5. What is the outlook for Cortisporin in emerging markets? Emerging markets represent a potential growth area due to increasing healthcare access and demand for affordable generic medications, offering volume expansion opportunities for Cortisporin.

CITATIONS

[1] Mordor Intelligence. (n.d.). Ophthalmic Drugs Market - Growth, Trends, COVID-19 Impact, and Forecasts (2023 - 2028). Retrieved from [Specific URL if available, otherwise general source description]. [2] Grand View Research. (n.d.). Ophthalmic Drugs Market Size, Share & Trends Analysis Report By Drug Type (Anti-infectives, Anti-glaucoma, Anti-inflammatories, Anti-allergy), By Disease Indication, By Region, And Segment Forecasts, 2023 - 2030. Retrieved from [Specific URL if available, otherwise general source description]. [3] U.S. Food and Drug Administration. (n.d.). Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. Retrieved from [Specific URL if available, otherwise general source description]. [4] Centers for Disease Control and Prevention. (n.d.). Antibiotic Resistance. Retrieved from [Specific URL if available, otherwise general source description]. [5] Pharmaceutical industry reports and company filings (specific company names and report titles would be listed if directly referencing publicly available data for market analysis).